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Abstract: Complex molecular and cellular mechanisms are involved in the pathway of liver fibrosis. Activation and 
transformation of hepatic stellate cells (HSCs) are considered the two main reasons for the cause and development of liver 
fibrosis. The peroxisome proliferator-activated receptors (PPARs) belonging to the family of ligand-activated transcrip-
tion factors play a key role in liver homeostasis, regulating adipogenesis and inhibiting fibrogenesis in HSCs. Normal 
transcriptional function of PPARs contributes to maintain HSCs in quiescent phase. A reduced expression of PPARs in 
HSCs greatly induces a progression of liver fibrosis and an increased production of collagen. Here, we discuss role and 
function of PPARs and we take into consideration molecular factors able to reduce PPARs activity in HSCs. Finally, al-
though further validations are needed, we illustrate novel strategies available from in vitro and animal studies on how 
some PPARs-agonists have been proved effective as antifibrotic substances in liver disease. 
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1. INTRODUCTION 
Molecular and gene studies have opened new points of 
view on the pathogenesis of liver fibrosis clarifying some of 
the most important pathophysiologic mechanisms, among 
which very important is the one involving the role of perox-
isome proliferator-activated receptors (PPARs) in hepatic 
stellate cells (HSCs) (Fig. 1). 
PPARs, belonging to the nuclear hormone receptor su-
perfamily, are transcription factors that bind DNA and regu-
late transcription in a ligand-dependent manner. They regu-
late gene expression after binding with RXR (Retinoid X 
Receptor) as a heterodimeric partner to specific DNA se-
quence elements termed PPRE (peroxisome proliferator re-
sponse element [1]. 
Three main isotypes of PPARs, PPAR  (also called 
NR1C1), PPAR  and   (PPAR  /  ) that are the same recep-
tor (also called NUC1 or FAAR), and PPAR  (also called 
NR1C3), are known: each one of them has a distinct, tissue-
specific pattern of expression [2]. 
PPARs control the transcription of several genes in-
volved in fatty acid oxidation and cell differentiation and 
regulate several biological processes such as development, 
differentiation, neoplastic conversion, inflammation and 
wound healing [3]. 
In the liver, PPARs have important functions: they con-
tribute to maintain HSCs in a quiescent condition; indeed, 
PPAR  is able to inhibit type I collagen expression at the 
level of transcription [4]. HSCs, that are pleiotropic cells 
strictly located next to hepatocyte laminates in the  
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perisinusoidal space of Disse, whether activated or trans-
formed, greatly favour the development of liver fibrosis [5] 
(Fig. 2).  
In HSCs, equilibrium between adipogenic and myogenic 
genes is also regulated by epigenetic modifications. Despite 
the mechanism is largely unknown yet, DNA methylation in 
CpG islands of the gene promoter regions seems very impor-
tant. Several studies demonstrated an increased hypermethy-
lation rate of promoter in cirrhotic patients compared to 
normal controls [6, 7]. 
Depletion of microRNA132 (miR132) leads to over-
expression of methyl-CpG binding protein 2 (MeCP2), that 
normally is suppressed. MeCP2 induces generation of en-
hancer of zeste homolog 2 (EZH2) and hypermethylation of 
lysine 27 histone 3 (H3K27). Alternatively, MeCP can di-
rectly bind CG island and promote methylation of H3K9. 
Methylated H3K9 can recruit transcriptional suppressor 
HP1  and bind to the promoter, exon1, exon2 and 5’ end of 
PPAR . All these mechanisms conduct to a suppression of 
PPAR  [8, 9].  
Another pathway shows a key role of necdin: this pro-
tein, normally expressed in neurons, skeletal and smooth 
muscle cells, can prevent HSCs from developing adipogenic 
characters. In fact, Necdin combines with GN box of pro-
moter of wingless-related MMTV integration site 10b 
(Wnt10b). Promotion of Wnt10b expression leads to the 
generation of EZH2 and hypermethylation H3K27 [10]. 
Also MeCP2 enhances the expression of a methyltrans-
ferase of H3K4 promoter called ASH1 that leads to recruit-
ment of  -SMA, collagen I, TIMP-1 and TGF 1 genes [11]. 
MeCP2 is also partially involved in epigenetic regulation 
of expression of inflammation chemokine [12]. 
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Fig. (1). Schematic view of the portal microcirculation under physiological conditions of the liver: you can see the portal sinusoid with, 
around, space of Disse, hepatic stellate cells (HSCs) and hepatocytes. PPAR  inside HSCs and PPAR  and PPAR /  inside hepatocytes are 
respectively involved in favouring the maintainance of normal liver function and metabolism. 
 
 
 
Fig. (2). Schematic view of the portal microcirculation in liver fibrosis: portal sinusoid with increased amount of collagen type 1 in space of 
Disse, activated hepatic stellate cells (HSCs) and hepatocytes are represented. PPAR  inside HSCs and PPAR  and PPAR /  inside hepato-
cytes are respectively altered and liver function is dysregulated. 
Another epigenetic mechanism involves metalloprote-
ases: an impaired histone deacylation during HSC differen-
tiation may lead to accumulation of histone deacetylase-4, 
which can suppress the activity of MMP gene promoter in 
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quiescent HSCs, determining accumulation of extracellular 
matrix [13]. 
The telomere length may play an important role. Previous 
studies demonstrate that hypermetilation of DNA is corre-
lated with an increased activity of telomerase [1]. This epi-
genetic mechanism seems to be involved in trans-
generational inheritance: in 2009, it was demonstrated that 
offspring of murine models exposed to CCL4 injury devel-
oped tolerance to liver damage and a lower degree of fibrosis 
[14]. 
Epigenetic mechanisms, although largely unknown, seem 
to be a very intriguing area of research for the next years. 
Before HSCs transform themselves into myofibroblasts, a 
number of stimuli (viral, ROS, endotoxins, alcool, etc) act on 
several cellular types in the liver (Kupffer cells, macro-
phages, neutrophils, T cells, natural killer and natural killer T 
cells) [15]; these cells secrete specific cytokines to favour 
initiation and progression of hepatic fibrosis by means of a 
reduction of activity of PPARs in HSCs. Indeed, TNF-  me-
diated inhibition of PPAR  transactivity may result in in-
creased HSCs activation and proliferation [16, 17]. 
It is known that the activity of PPARs depends on ligand-
induced conformational changes, a mandatory process for a 
correct functioning of ligand-regulated nuclear receptors 
[18]. Conformational changes of PPARs facilitate their dis-
sociation from corepressor molecules and their interaction 
with multisubunit coactivators. 
Therefore, lack of dynamic and coordinated changes in 
PPARs expression and also perturbations in the expression 
of coactivators may alter the correct function of PPARs and 
favour a change of phenotype from quiescent to activated in 
HSCs. 
Inhibition of fibrosis is one of the most attractive biologi-
cal process, object of several studies [19]. Here we want to 
review the complex molecular mechanisms and the signaling 
involved in the cross-talk among coactivators, corepressors 
and PPARs in HSCs.  
We also summarize some of the several strategies based 
on PPAR  stimulation that have proven to be potential anti-
fibrotic approaches. 
2. PPARS IN LIVER PHYSIOLOGY 
2.1. Str ucture of PPARs 
PPARs share a similar modular structure: A/B domain 
(ligand- independent activation domain), C domain (DNA 
binding domain), D domain (hinge domain), and E/F domain 
(ligand-binding domain – LBD) [20]. The chief fragment of 
the N-terminal domain A/B is an  -helix fragment possess-
ing a ligand-independent activating function (AF-1) [21]. In 
A/B domain there is a residue of serine in position 112, sub-
ject to phosphorylation by mitogen-activated protein kinase 
(MAPK) pathway, resulting in failure to intramolecular 
communication between the domains, and reduction in 
ligand-binding affinity. C domain contains two zinc fingers, 
each encoded by two different exons (2 and 3) which, to-
gether with particular aminoacid sequences, binds DNA. C 
domain also takes part in dimerization with RXR. D domain 
is a flexible hinge between C and E / F domains [22]. It acts 
as a binding cofactor and contains a specific amino acid se-
quence recognized by the transport proteins, which allows 
the movement of the protein synthesized, from the cytoplasm 
to the nucleus. The largest domain is the LBD (E/F domain) 
located at the C-terminus [23]. The LBD contains a fragment 
called ligand-dependent activation function 2 (AF-2), en-
gaged in the recruitment of PPAR  cofactors to assist the 
gene transcription processes [24].  
The unliganded LBD possesses a small  -sheet of four 
strands and 12  -helices that are folded into three layers to 
create a central hydrophobic ligand-binding pocket. AF-2 is 
in helix 12, located between  -strand and helix 3, that closes 
the ligand binding site in response to a ligand, resulting in a 
transcriptionally active form of the receptor [25].  
Despite this similar structure, the difference between 
PPARs can be linked to ligand specificity. In this regard, 
PPAR  cavity is narrower in the region adjacent to the AF-2 
helix and this may explain why large headed TDZs and L-
tyrosine based agonists show little or no ability to bind 
PPAR  [26]. 
The difference between PPAR  and PPAR  may be ex-
plained by the interaction with Farglitazar and GW409544: 
in fact, Farglitazar, shows higher PPAR  selectivity com-
pared to that of GW409544, due to the presence of three ad-
ditional atoms located near the carboxylate head group. Due 
to the presence of Tyr314 in PPAR  compared to the corre-
spondent His 323 in PPAR , farglitazar shows stearical clash 
in interaction with PPAR  [26]. 
Regarding LBD, a “mouse trap model” was proposed 
[27] whereby a ligand-induced conformational transition 
permitted the reposition of the amphipathic alpha-helix of 
the AF-2 activating domain and, forming the active form of 
the receptor that can bind a co-activator. 
This is crucial in the interaction with the agonist 
GW1929, a pan-agonist that stabilizes H11 and H12, in con-
trast with the partial agonist nTZDpa and the antagonist 
GW9662 [28]. Furthermore PPAR  and PPAR  show that 
H12 is very dynamic even in the absence of ligand, and can 
adopt the active form spontaneously [29], in agreement with 
the existence of a basal activity in the absence of ligand [30]. 
These conformational changes, that can ensure a constitutive 
activity of PPARs, depend on highly conserved residues 
among the three isotypes [31, 32].  
Allosteric alterations are also important in regulation of 
PPARs with coactivators and corepressors, that stabilize the 
molecule in an active and, respectively, inactive form. The 
nuclear receptor interaction domain of the co-activators con-
tains LXXLL motif that forms two turns of  -helix and binds 
into a hydrophobic cleft on the surface of the receptor. The 
latter is formed upon stabilization of active conformation of 
AF-2 in H12 [33].  
Corepressor motif instead is LXXXIXXXL, that reposi-
tions the AF-2 helix and prevents it from going back to ac-
tive positions [34]. 
2.2. PPAR    in Hepatocytes 
Peroxisome proliferator-activated alpha, also known as 
PPAR , NR1C1; hPPAR; MGC2237; MGC2452, is a nu-
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clear-hormone transcription receptor of 468 amino acids 
coding by 22q13.31 [35]. 14 polymorphisms are known, at 
least (Table 1) [36]. 
Table 1. PPAR  Polymorphisms 
P22R 
V227A (rs1800234) 
A268V (rs1042311) 
D140Y 
D304N (rs1800242) 
R127Q (rs1800204) 
G395A (rs2229245) 
R131Q 
D409T (rs1800243) 
L162V (rs1800206) 
R178G 
Q413L (rs9615759) 
D140N 
G395E 
 
The expression of the PPAR  gene is regulated by the 
hepatocyte nuclear factor-4 (HNF4), that enhances hPPAR   
promoter activity. In contrast, the nuclear receptor COUP-
TFII down-regulates the hPPAR   promoter activity. PPAR  
binds the  HNF4-RE, leading to its expression in hepato-
cytes [37] that is regulated by the ubiquitin proteasomal deg-
radation system [38].  
PPAR  is regulated also by repressive post-trascriptional 
mechanisms such as  
- PPAR 2, a A truncated isoform resulting from a post-
translational exon skipping [39]  
- post-translational modifications such as phosphoryla-
tion, [40-42]. 
PPAR , like many non-steroid members of the nuclear 
receptor (NR) family, functions as an obligate heterodimer 
with another nuclear receptor, retinoid X receptor (RXR; 
NR2B) [43]. The PPAR /RXR heterodimers can form inde-
pendently of the PPAR  ligand and these unliganded het-
erodimers recruit corepressor protein complex and inhibit 
target genes transcription [44]. Upon ligand binding, the 
corepressor complex is released from the PPAR /RXR het-
erodimer, and the coactivator complexes will be recruited to 
the promoter region of target genes to initiate transcription 
[5]. The PPAR /RXR heterodimers bind to a specific DNA 
sequence element called peroxisome proliferator response 
element (PPRE) [45]. 
RXR is also partner of other NRs; a possible competition 
mechanism between NRs for this common binding partner 
may exist [46]. Transcriptional activation of genes is a com-
plex process, which involves the participation of several 
transcription coregulators. PPAR , interacting with coactiva-
tors or corepressors, augments or represses, respectively, its 
activity [47] (Table 2) [36]. 
The binding of ligand to a nuclear receptor favors  
•  the release of corepressors through the recruitment of 
coactivator complexes, such as members of the SRC-
1/p160 family, which exhibit histone acetyltransferase 
activity required to facilitate chromatin remodeling.  
•  the docking of other coregulators, either singly or as 
preassembled multisubunit protein complexes, including 
mediator complex (MED),  
•  the interaction of ligand-activated receptor with RNA 
polymerase  
•  the transcription of a specific set of genes [48] 
All PPARs participate in energy metabolism: PPAR  and 
PPAR /  act as catabolic regulators of energy expenditure, 
while PPAR  regulates anabolic metabolism [49]. Hepatic 
lipid metabolism principally involves three aspects: lipo-
genesis, oxidation of fatty acids and secretion of lipids. 
Emerging evidence suggests that PPAR  also influences 
lipogenesis by increasing the transcription of Scd-1 and other 
lipogenic genes by regulating the primary transcription fac-
tors liver X receptor   (LXR ).  
This function is regulated by the LXRs ligand activation 
that represses PPAR  signaling through reduction of stimu-
lated-PPAR /RXR binding to PPRE, as observed in primary 
culture of hepatocytes and mouse liver [50, 51]. Another 
transcription factor, regulator of the hepatic lipogenesis, and 
inhibitor of PPAR  is SREBP-1c [52]. 
The involvement of PPAR  in lipogenesis may suggest a 
fail-safe compensatory mechanism for the removal of impor-
tant fatty acids, for example, during starvation [53]. 
Table 2. Corepressor  and Coactivator s of PPAR  
PPAR  Corepressor  PPAR  Coactivator s 
N-CoR (nuclear corepressor) 
SMRT (silencing mediator for retinoid and thyroid hormone receptors) 
Receptor Interacting Protein 140 (RIP140) 
SRC-1 (steroid receptor coactivator-1) 
CBP/p300 
SRC/p160 family 
PBP/MED1 (PPAR-binding protein/TRAP220/DRIP205/ mediator subunit 1) 
PRIP/NCoA6 (ASC2/RAP250/TRBP/NRC) 
PRIC285 
PRIC295 
PRIC320 
PGC-1  
PGC-1 , as well as coactivator-associated proteins PIMT (NCoA6IP) and 
CARM-1 
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PPAR  regulates fatty acid oxidation in the hepatocytes 
acting on genes of the classical inducible peroxisomal ( -
oxidation and microsomal  -oxidation) and key enzymes 
(Table 3) [54]. 
Dicarboxylic acids are unique because they serve as sub-
strates for the peroxisomal  -oxidation system and also as 
ligands for PPAR , streamlining their own metabolism by 
inducing PPAR  activation and thus regulating all three fatty 
acid oxidation enzyme pathway.  
PPAR  may be activated by several endogenous mole-
cules, such as satured and unsatured long chain fatty acyl-
CoA and unsatured long chain fatty acids, through ligand-
induced conformational changes (large molar ellipticity 
changes) [55].  
The most studied endogenous PPAR  ligand is the 1-
palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine16:0/18:1-
GPC (1); it has been demonstrated to be able to induce 
PPAR -dependent gene expression and to decrease hepatic 
steatosis when fatty acid synthase enzyme activity is present 
[56, 57]. Another endogenous molecolar factor able to re-
duce hepatic fat accumulation is adiponectin, an adipocyte 
produced peptide hormone that, by means of activation of 
PPAR , induces hepatic fatty acid oxidation [58]. 
PO O
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O
O
O
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PPAR  ligands reduce very low density lipoprotein 
(VLDL) production and enhance the catabolism of triglyc-
erides (TG)-rich particles and this indirectly decreases small 
dense LDL (sdLDL) particles [59, 60], enhancing the forma-
tion of high density lipoprotein (HDL) particles and hepatic 
elimination of excess cholesterol. The activity of ApoC-III, 
which is an inhibitor of both lipoprotein lipase (LPL) activity 
and remnant clearance, is lowered by PPAR  agonists. HDL 
apolipoprotein genes apoA-I and apoA-II are activated by 
PPAR  by direct transcriptional control [61]. Thus, PPAR  
activation by fibrates and other compounds, elicits a global 
normolipidemic response, by reducing TG-rich particle pro-
duction, increasing their lipolysis, and promoting HDL me-
tabolism. PPAR  also shows an important role in reducing 
inflammation. In fact, Leukotriene B4 (LTB4) is a PPAR  
agonist and a powerful chemotactic inflammatory eicosa-
noid. Stimulation of PPAR  by LTB4 causes expression of 
genes of the  - and  -oxidation pathways that neutralize and 
degrade LTB4 itself [62].  
2.3. PPAR  /  in Hepatocytes 
PPAR / , also known as FAAR, NUC1, NUCI, NR1C2, 
NUCII, PPAR , PPAR , is coded by chromosome 6p21.2 
and exists in at least 3 isoforms: 401, 361 and 402 amino 
acids generated by alternative splicing. [63]. An interesting 
study demonstrated that PPAR /  has a molecular structure 
very similar to that of PPAR  [64]. PPAR /  as other 
PPARs, forms an obligate heterodimer with RXR and binds 
to specific PPRE found on target genes [65]. Post-
transcriptional modifications include phosphorylation, ubiq-
uitinylation, and sumoylation [47]. PPAR /  expression is 
induced by protein kinase C (PKC) activation [66] which 
plays an important role in inflammation. After post-
transcriptional modifications, PPAR /  activates or represses 
target genes depending on cellular expression pattern of co-
activators and co-repressors [67].  
PPAR / , unlike PPAR  and PPAR  that are localized 
mostly in the liver and adipose tissue, is ubiquitous, but has a 
higher expression in intestine, keratinocytes and liver [68]. 
PPAR /  is expressed in quiescent HSCs, and especially 
in activated HSCs in vitro and in vivo but its role is not com-
pletely clear yet; indeed PPAR /  favors HSCs proliferation 
but also counterbalances this effect expressing genes in-
volved in esterification of vitamin A (2) and downregulating 
proinflammatory gene expression, thus working to maintain 
HSCs in a quiescent phase [69-71].  
Liver function of PPAR /  has been object of an interest-
ing study demonstrating that adenovirus-mediated liver-
restricted PPAR /  activation reduces fasting glucose levels 
in high fat- and in chow-fed mice with concomitant increase 
in accumulation of glycogen [72]. 
OH
2  
Studies on PPAR /  –/– mice have better clarified the 
principal function of this transcription receptor factor [73]. 
During normal diet, PPAR /  –/– mice have elevated plasma 
triglycerides and free fatty acids, but normal values in either 
total cholesterol or phospholipids [74]. After a 10 weeks 
high fat diet, in comparison with wild-type controls, 
PPAR /  –/– mice have elevated serum values of triglyc-
Table 3. Genes and Protein Expressed by Activated PPAR  
Enzymes r egulated by PPAR  Genes r egulated by PPAR  
Long chain acyl-CoA synthetases 
carnitine palmitoyl transferase 
1,2-enoyl-CoA hydratase 
3-hydroxyacyl-CoA dehydrogenase 
3-keto acyl-CoA thiolase 
acyl-CoA oxidase 1, ACOX1 
hydratase-dehydrogenase multifunctional/bifunctional enzymes MFP1/L-PBE 
Pancreatic Trygliceride Lipase PTL 
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erides, an increased rate production of hepatic VLDL and 
lowered LPL [75]. According to these authors, PPAR /  
plays a key role in regulating levels of serum triglycerides in 
high fat fed mice, by modulating both VLDL production and 
LPL-mediated catabolism of VLDL-triglycerides; this sug-
gests a potential therapeutic role for PPAR /  in improving 
serum lipids of patients with metabolic syndrome [75]. 
PPAR /  also up-regulates the fatty acid synthesis pro-
gram as well as the lipogenic transcription factor and co-
activator, SREBP-1c and PGC-1  [72]. In the same study, an 
increased resistance to steatohepatitis was demonstrated. 
These data suggest a role of PPAR /  in the elimination of 
potentially toxic lipid through the accumulation of TG or 
their transformation into less toxic lipids. Paradoxically, a 
link between PPAR /  and AMP-activated protein kinase 
(AMPK) determines suppression of lipogenesis and glyco-
gen synthesis [76]. Interestingly, adPPAR /  livers have 
increased expression of adiponectin receptor 2: therefore, a 
further activation of AMPK may be due to adiponectin [72].  
PPAR /  cells also contribute to lower the level of pro-
inflammatory molecules functioning as a nuclear sensor of 
dietary fats capable of modulating the immune response 
through regulation of metabolic programs [72, 77]. 
Finally, it has been shown that PPAR /  has hepatopro-
tective effects being able to modulate NF-kB signaling thus 
attenuating carbon tetrachloride hepatotoxicity [78]. 
Also it has been shown that agonists for all three PPARs 
(GW7647 for PPAR , GW0742 for PPAR , and BRL49653 
(rosiglitazone) for PPAR ) decrease leptin and interleukin-6 
secretion whereas PPAR  and PPAR /  agonists increase 
hepatocyte growth factor secretion [79]. Therefore adipo-
cytes are stimulated to produce IL 13 and 4, which in turn 
allows the macrophage PPAR /  overexpression [80]. Thus, 
there is a decrease in inflammation which is connected to 
increased insulin sensitivity of adipose tissue.  
2.4. PPAR  in Hepatic Stellate Cells 
Peroxisome proliferator-activated  , also known as 
GLM1, CIMT1, NR1C3, PPAR , is a human hormone re-
ceptor coded by chromosome 3p25 [81]; it includes 9 exons 
designated as follow: A1, A2, B, and 1–6. In humans, four 
different subtypes of PPAR  mRNA (  1,   2,   3, and   4) 
transcribed from four different promoters were found. [82-
84]. PPAR  1 predominates quantitatively. mRNA PPAR  1 
shows the highest expression levels in adipose tissue and in 
the large intestine, while it is barely detectable in the skeletal 
muscle [82]. hPPAR  2 and   4 mRNA appear to be limited 
to the adipose tissue [84], while hPPAR  3 mRNA is ex-
pressed in the large intestine, white adipose tissue (WAT) 
and macrophages [83]. Both promoter regions of mPPAR  1 
mPPAR  2 show consensus sequence-binding transcription 
factors such as CCAAT / enhancer binding protein (C / 
EBP), hepatocyte nuclear factor 5 and 3 (HNF5 and HNF3), 
and adipocyte determination and differentiation factor 
1/sterol response element binding protein 1 (ADD-1/SREBP-
1). However, unlike mPPAR  2, mPPAR  1 contains a large 
block (of Approximately 550 bp) of a (C + G)-rich sequence, 
suggesting the possibility of a methylation, resulting in inhi-
bition of the expression of the gene [85]. 
Despite four distinct mRNA subtypes, PPAR  exists in 
two protein isoforms (designated hPPAR  1 and   2) result-
ing from alternative promoter usage and alternative splicing 
at the 5’ end of the gene. hPPAR  1,   3, and -   4 mRNA 
give rise to an identical protein product, hPPAR  1 (477 aa). 
PPAR  1 is coded by exons A1,A2,1-6; PPAR  3 is coded 
by exons A2,1-6 and PPAR   4 is coded only by exons 1-6. 
hPPAR  2 mRNA encodes the hPPAR  2 protein with 30 
extra N-terminal amino acids (505 aa) encoded by the B 
exon [85]. 
PPAR  is a nuclear receptor factor whose principal func-
tion is to regulate the sinthesis of fibrogenic molecules such 
as TGF- ,  -SMA, suppressing expression of their genes; 
PPAR  has interactions with insulin pathway in HSCs im-
peding the development of insulin resistance, maintains 
normal plasma free fatty acids level, regulates cell growth 
and cell differentiation and thus helps control chemotaxis, 
prevent the induction of fibrosis and reduce the progression 
of preexisting fibrosis [4, 34]. 
Adiponectin seems to be the most important effector for 
PPAR  antifibrotic hepatic action [86]. 
PPAR  plays an important role in adipogenesis. First of 
all, PPAR  induces production of several specific adipose 
marker such as adipocyte fatty acid binding protein (aP2) 
[26], phosphoenolpyruvate carboxykinase (PEPCK) [27], 
and LPL [61]. PPAR  favours the differentiation and produc-
tion of small adipocytes, that are more insulin-sensitive than 
large adipocytes; PPAR  also induces apoptosis of large adi-
pocytes. This effect on differentiation of adipocytes is fa-
voured by TZD class drugs [28]. 
In adipogenesis, PPAR  shows a positive feedback with 
C/EBP transcription factors (C/EBP- , - , and  ): C/EBP   
and   are activated in response to insulin or glucocorticoids 
in the initial stage of adipogenesis and induce production of 
PPAR . In the final stage of this process PPAR  stimulates 
production of C/EBP  that, in turn, acts on the expression of 
PPAR  gene, binding the same DNA sites induced by 
C/EBP-  and   [29, 30]. This positive feedback can be 
blocked by TNF   with a lipid depletion and a complete re-
versal of adipocyte differentiation [31]. In addition, TNF   
suppresses several adipocyte genes, such as those encoding 
aP2, adipsin, and insulin-responsive glucose transporter 
(GLUT4) [32]. Leptin also controls this process, with the 
induction of lipolysis and glucose utilization in adipocytes, 
with a functional antagonism between C/EBP  and PPAR  
[33]. In addition, the transcriptional factor ADD1/SREBP1 
modulates PPAR  activity, through the production of en-
dogenous ligands for PPAR  [32]. 
The pivotal role of PPAR  in adipogenesis and lipid 
regulations is demonstrated also by the partial lipodystrophy 
in patients with several missense mutation in PPAR  [34]. 
Moreover, ectopic expression of PPAR  promotes adipo-
genesis in nonadipogenic fibroblastic cells such as NIH-3T3 
cells [87]. 
PPAR  plays an important role in insulin sensitivity as 
demonstrated by a polymorphism of PPAR  2, called 
Pro12A1a, that is associated with lower BMI and enhanced 
insulin sensitivity [88]. In mouse model in vivo, S112A mu-
tation preventing phosphorylation in Ser-112 of PPAR  im-
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peded obesity-associated to insulin resistance [89]. Studies in 
liver PPAR  knockout mice with adipose tissue, showed that 
they developed relative fat intolerance, increased adiposity, 
hyperlipidemia, and insulin resistance; PPAR  exhibits an 
impaired plasma uptake of TGs and TG deposition in muscle 
and adipose tissue, that contributes to insulin resistance [90]. 
Thus hepatic PPAR  contributes to TG homeostasis, regulat-
ing both TG clearance and lipogenesis.  
The similarities between HSCs and adipocytes are de-
duced from several circumstances: HSCs express adipocyte-
specific genes such as leptin [91], adiponectin [92], resistin 
[93] and adipsin [94] and have the capacity to accumulate 
triglycerides as well as adipocytes [95]. Quiescent HSCs 
express type IV collagen similarly to adipocytes, whereas the 
activated HSCs express collagen type I and III as well as 
fibroblasts preadipocytes [9]. Cytokines and growth factors 
which block the differentiation of adipocytes (Epidermal 
growth factor/TGF alfa, TGF beta, TNF alfa, IL-1, monocyte 
chemotactic protein 1 [MCP-CCL2]) activate also the HSCs, 
suppressing the expression of adipogenic transcription fac-
tors (CCAAT/enhancer binding protein [C-EBP  ,   and  ], 
sterol, regulatory elementi binding protein-1c [SREBP-1c], 
LXR  , PPAR  , etc.) [96]. 
PPAR   is the most important regulator of adipocytes dif-
ferentiation and the central element in the process of activa-
tion and transdifferentiation of HSCs. PPAR  activated by 
ligand plays an important role in reducing and preventing 
liver fibrosis [97]. 
Recently, it has been demonstrated that the adenovirus-
mediated expression of PPAR  in activated HSCs determines 
the suppression of production of type I collagen,   smooth 
muscle actin and TGF  1 (typical of activated HSC) and the 
restoration of the ability of HSCs to accumulate retinyl 
palmitate, unique and specific function of quiescent HSCs in 
vivo [98]. This method allowed to avoid the use of agonists 
that may have receptor-independent effects. 
The similarity between adipocyte and HSCs, due to the 
common mesenchymal origin, is not total: HSCs in fact ex-
press PPAR   1, whereas adipocytes express PPAR   2 [4]. 
3. PPARs IN LIVER FIBROSIS 
3.1. PPAR    in Hepatocytes 
In neither rodents nor in human HSCs, PPAR  mRNA is 
found [99]. However, quite recently, the pivotal role of 
PPAR  in alcoholic liver disease was highlighted [100].  
In cultured hepatoma cells, ethanol inhibits PPAR  tran-
scriptional activity to bind its PPRE consensus sequences 
[50]. This inhibitory effect was confirmed in vivo on ethanol 
fed Sv/129 mice and rats [50]. 
Acetaldehyde, a hepatotoxic molecule, is produced by 
ethanol oxidation mediated by alcohol dehydrogenase [101, 
102]; this metabolite inhibits PPAR  activation of receptor 
genes and prevents PPAR  and PPAR  retinoid X receptor 
(RXR) from interacting with DNA [103, 104]. 
Acetaldehyde, and more generally ethanol metabolism, 
slows down the response of hepatocytes to free fatty acids 
mediated by PPAR  [100]. PPAR  promotes the expression 
of catalase and Cu2+,Zn2+ - superoxide dismutase (SOD1), 
that play an anti-oxidative role [105, 106]; in presence of 
acethaldeyde, PPAR  is hampered in performing its anti-
oxidative function and oxidative stress increases. 
In patients with alcohol liver diseases, an increased 
plasma level of endotoxin was detected [107-111] compared 
to healthy people and non-alcoholic cirrhotic patients; TNF  
and TNF  soluble receptors have been shown to correlate 
with the degree of endotoxemia and liver disease stage in 
patients with alcoholic liver disease [107]. These findings 
may be motivated in chronic ethanol users by an increased 
intestinal permeability that persisted after two weeks of so-
briety [112, 113]. 
In alcoholic liver disease, inflammation response plays a 
pathophysiological role, involving TNF , NF-kappaB, adi-
ponectin, LPS, Kupffer cells, HSCs and PPAR . In 2004, a 
relationship was demonstrated between the tumor necrosis 
factor/nuclear factor-kappaB (TNF/NF-kappaB) pathway 
and PPAR  in PPAR  knockout mice that were fed with a 
diet containing 4% ethanol for six months; mice showed 
hepatomegaly, hepatic phlogosis, cell toxicity, fibrosis, in-
crease of apoptosis and mitochondrial swelling and changes 
in ethanol and acethaldehyde metabolism, oxidative stress, 
inflammation, hepatocyte proliferation, fibrosis and mito-
chondrial permeability transition activation [114]. These 
findings may be explained by two molecular mechanisms of 
PPAR : transactivation and transrepression [115, 116]. 
Transactivation of PPAR  requires a direct inhibitory inter-
action with p65, one of two components of NF-kappaB, on 
NF-kappaB transcription with the induction of a co-activator 
[100]. Transrepression of PPAR  involves an indirect inhibi-
tion of NF-kappaB transcription through induction of 1-
kappaBalpha, which binds NF-kappaB, preventing its trans-
location into the nucleus. 
An increase in plasma endotoxin and endotoxin-induced 
cytokines, as TNF , IL1, IL2, IL6 and IL8, was hypothe-
sized to have an important role also in pathophysiology of 
steatohepatitis [100].  
Indeed, in animal models, the dysfunction of PPAR  is 
implicated in the pathogenesis of steatohepatitis [117]; the 
ensuing suspicion that the dysfunction of PPAR  may con-
tribute to alcoholic and non-alcoholic steatohepatitis is also 
great in humans since its dysfunction is associated with he-
patic lipid accumulation [118, 119]. 
Hepatocyte damage, inflammation and fibrosis are the 
key factors that promote the progression from simple steato-
sis to steatohepatitis [176]. Activated HSCs significantly 
contribute to cytokine expression during steatohepatitis. Fat 
accumulation in the liver induces hepatic cell cytotoxicity 
either directly or through sensitization of other agents that, 
together with the increased cytokine production and reactive 
nitrogen species, contribute to imbalance mithocondrial 
function [176]. Mithocondrial dysfunction favours fatty acid 
oxidation and generation of reactive oxigen species. Moreo-
ver, the HCV core protein down-regulates the expression of 
PPAR  and steatosis may also result as a direct consequence 
of viral protein infection in HCV genotype 3 infection [120, 
121].  
PPARs and Liver F ibrosis Current Medicinal Chemistry, 2013, Vol. 20, No. 27    3377 
All of this causes hepatocyte damage, oxidative stress, 
inflammation, endoplasmic reticulum stress and insulin resis-
tance whose direct effect is to cause an elevated insulin sig-
naling that stimulates HSCs activation by inducing mito-
genesis and collagen synthesis [122]. The final outcome, 
through the passage to HSCs activation and transformation, 
is liver fibrosis [123].  
PPAR  demonstrates an anti-inflammatory role during 
the course of cytokine-induced phlogosis; but since acetalde-
hyde inhibits the physiological function of PPAR , chronic 
ethanol use impairs the anti-inflammatory role of PPAR  
[114, 124, 125]. 
Adiponectin is an adipokine produced by adipocytes and 
fat tissues [126, 127]. Decreased levels of adiponectin are 
associated with obesity [128], type II diabetes [129, 130], 
atherosclerosis [131], inflammation [128] and animal models 
of alcoholic and non-alcoholic liver disease [132, 133]. In 
2003, it was demonstrated that chronic assumption of an 
high-fat, ethanol-containing diet reduced adiponectin serum 
levels by 30-40% after three to four weeks; the decrease of 
adiponectin correlated with the development of liver damage 
in mice [132]. Indeed, adiponectin activates PPAR  and 
impairs sterol regulatory element binding protein-1 (SREBP-
1); therefore, in alcoholic liver disease, adiponectin may play 
its hepatic protective role regulating trascriptional factors 
that, in turn, control fatty acid synthesis [134-136] by means 
of PPAR . 
3.2. PPAR /  in Hepatocytes 
PPAR /  has a pivotal role in metabolic homeostasis and 
disorders. The reported effects of PPAR /  ligands include: 
correction of dyslipidemia and hyperglycemia, prevention of 
diet-induced obesity, increase of insulin sensitivity and 
modulation of muscle fiber type switching [137-139]. They 
may be due to increased fatty acid catabolism and mithocon-
dria function in muscle and adipocytes [140]. PPAR /  acti-
vation also shows anti-inflammatory properties by inhibition 
of macrophage activation [80, 141]. 
In particular, it was showed that PPAR /  activation 
leads to an increased glucose utilization in mice liver, as 
evidenced by the fact that adPPAR /  mice had lower fast-
ing glucose levels compared with controls [80]. PPAR /  
increases through the activation of AMPK, glycogen synthe-
sis and lipogenesis; the ensuing increase of monounsaturated 
fatty acids (MUFAs) is in turn activator of PPAR /  that 
may protect the liver from free fatty acid-mediated lipotoxic-
ity and inflammation [72]; PPAR /  also sustains hepatic 
glucokinase (GK) levels leading to glycogen accumulation 
after fasting [72]. PPAR /  induces glucose-utilization in 
hepatocytes by direct and indirect transcriptional mecha-
nisms [72]. The induced lipogenic activity suggests a 
PPAR /  role in steatosis and steatohepatitis. adPPAR  /  
mice had not liver disease neither in normal nor in high diet, 
as shown by transaminases normality; adPPAR /  mice ex-
hibited decrease of Jun N-terminal kinase (JNK) signaling 
and inflammatory markers [72]. Free fatty acids cause lipo-
toxicity, which induces inflammatory response; it is possible 
that PPAR  / , inducing partitioning of fatty acids for 
triglyceride synthesis, protects from free fatty acids damage. 
Indeed, in hepatocytes, PPAR /  suppresses fatty acid-
induced JNK activation and increases insulin-stimulated Akt 
phosphorylation; this may be the cause of the improved insu-
lin tolerance test observed in high fat-fed adPPAR  /  mice 
[72]. adPPAR /  mice livers contain more MUFAs and less 
saturated fatty acids [72]; therefore, PPAR /  may induce 
free fatty acid storage and/or convert hepatotoxic lipids into 
less toxic or protective forms. PPAR-beta/delta activity is 
associated with AMPK activation [76]. AMPK suppresses 
lipogenesis and glycogen synthesis [142, 143]. Probably, 
AMPK pathway acts as a negative feedback for PPAR / , 
and this may explain why long term PPAR /  treatment do 
not produce lipid accumulation in the liver [138]. PPAR /  
could function as a nuclear sensor of dietary fats able to con-
trol immune response through regulation of metabolic path-
ways. In fact, PPAR /  produces MUFAs which, in turn, 
activates macrophage or Kupffer cells PPAR /  to modulate 
immune response [72]. So, the expression of inflammatory 
markers, as TNF  or IFN , is reduced [72]. 
Therefore, PPAR /  activation exerts multiple functions 
such as sustaining a program of macrophage and Kupffer cell 
activation in metabolic tissues (in liver it prevents steatohe-
patitis), suppressing tissue inflammation, increasing oxida-
tive lipid catabolism in the liver, ameliorating serum lipid 
profiles and global insulin sensitivity, favoring weight loss in 
obesity [74]. 
Interestingly, PPAR /  may upregulate PPAR  expres-
sion, thus, indirectly, stimulating lipid metabolism and in-
creasing the synthesis of HDL, apoAI, apoA-II and apoA-III 
[137]. 
3.3. PPAR  in Hepatic Stellate Cells 
Upon hepatic injury, HSCs become activated and un-
dergo transdifferentiation from non-proliferating cells, stor-
ing vitamin A and lipid droplets, to myofibroblasts produc-
ing collagen, particularly type I. These myofibroblasts play a 
pivotal role in liver fibrogenesis increasing extracellular ma-
trix. HSCs activation is mediated by several cytokines and 
chemokines [144]. PPAR  is proven to be a key factor in 
HSCs activation and phenotype alteration [145]; indeed, 
HSCs activation is characterized by a PPAR  expression. 
Ectopic PPAR  expression or PPAR  ligands may also bring 
HSCs back to quiescent form and decrease collagen secre-
tion in vitro and in vivo [4, 19, 17]. Several studies show that 
PPAR  manages to keep HSCs in quiescent phase regulating 
many trascription factors, such as CCAAT/enhancer binding 
protein (C/EBP), LXR  and sterol regulatory element-
binding proteins-1c (SREBP-1c), which are depleted when 
HSCs are activated [146]. Moreover, adipogenic transcrip-
tional regulation in HSCs by PPAR  is important also in 
packaging of chromatin because DNA methylation inhibitor 
blocks myofibroblastic transdifferentiation of HSCs and pre-
vents the diminished PPAR  expression in HSCs [147]. 
Therefore, PPAR  is an important factor that helps to main-
tain HSCs in quiescent form and exerts anti-fibrotic actions 
in the liver [148]. The precise molecular mechanism underly-
ing the anti-fibrotic actions of PPAR  is largely unknown, 
but some mechanisms have been elucidated. Transforming 
growth factor-  (TGF ), and particularly TGF 1, is a key 
mediator implicated in liver fibrosis [144]. Following activa-
tion due to liver damage, TGF 1 binds its receptors (T R1 
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and T R2), allows the phosphorylation of Smad2 and Smad3 
and permits Smad2/3 to associate with Smad4; the signaling 
pathway traslocates to the nucleus and initiates the transcrip-
tion of several genes, including collagen I and III [144]. 
Smad6/7 represents the inhibition mechanism of this path-
way, being able to divide Smad2/3 from the receptor [149]. 
Activated HSCs express TGF 1 and Smad 2, 3, 4 and 7, but 
Smad7 appears to be silenciated [149]. The TGF /Smad 
pathway may play a pivotal role in liver fibrogenesis medi-
ated by activation of HSCs. PPAR  can prevent the function 
of TGF /Smad pathway in profibrotic myofibroblasts [150]. 
PPAR  inhibits the secretion of connective tissue growth 
factor (CTGF) induced by TGF  [151]; this suppression can 
be completely rescued by Smad3 overexpression but not by 
Smad4 [144]. PPAR  has the ability to divide the bond be-
tween the complex TGF-beta1-activated Smads and their 
response elements, thus reducing collagen I secretion. 
Platelet-derived growth factor (PDGF) is another impor-
tant profibrotic mediator for HSCs activation and hepatic 
fibrogenesis; PDGF is formed by a disulfide-linked dimeric 
protein composed by various combinations of four polypep-
tide chains (A, B, C and D). PDGF exerts its function after 
binding with its tyrosine kinase receptor PDGF R and 
PDGF R. Quiescent HSCs have not PDGF R, but, after 
their activation, HSCs begin to express this receptor and in-
crease their responsivity to PDGF-B [152]. More recently, an 
implication in liver fibrogenesis for PDGF-C and PDGF-D 
was demonstrated [153, 154]. PPAR  is involved in oppos-
ing PDGF action; PPAR  ligands or transfection with 
PPAR  decrease PDGF-induced human HSCs proliferation 
in in vitro studies [19, 155]. PPAR  activation inhibits ex-
tracellular factor-regulated kinases (ERK) activity and 
PDGF-induced c-Fos promoter activity, suggesting that 
PPAR  can affect the intracellular transduction signal of 
PDGF [156]. 
Hepatocyte growth factor (HGF), a mitogen for hepato-
cytes, induces cellular growth, motility and morphogenesis 
and its receptor is identified in c-Met [157]. HGF can pre-
vent liver fibrogenesis. In vivo, in distinct animal models, 
HGF has proven to be able to reduce HSCs activation and 
collagen secretion and to facilitate liver recovery after injury 
[158-160]. Probably, HGF antifibrotic action is due to dis-
ruption of TGF 1 signaling [161]. PPAR  may induce HGF 
promoter activity and increase HGF mRNA in fibroblasts 
[162, 163]. 
Many studies, in vitro and in vivo, elucidated that leptin 
is a potent stimulator of HSCs profibrogenic transformation: 
leptin may induce proliferation, prevent apoptosis, mediate 
collagen secretion and increase secretion of proinflammatory 
cytokines in the liver [164-167]. Leptin may induce HSCs 
phagocytosis, activate Kupffer cells and macrophages and 
stimulate hepatic sinusoid endothelial cells to produce TGF  
[168]. In vitro, leptin reduces PPAR  gene expression [169], 
whereas, in vivo, it induces suppression of PPAR  protein 
expression in HSCs, probabily through leptin-induced 
ERK1/2 activation [170]. 
On the contrary, adiponectin has proven to be a beneficial 
molecule in liver fibrogenesis and inflammation: adiponectin 
knockout led to develop severe liver fibrosis [171]. Current 
knowledge about the anti-fibrogenetic effect of adiponectin 
includes induction of caspase-dependent apoptosis in acti-
vated HSCs [172], upregulation of AMPK and inhibition of 
AKT pathway [173], activation of mitochondrial respiratory 
chain complexes involving uncoupling protein 2 [174] and 
recruitment of Kupffer cells [144]. PPAR  plays a critical 
role in adiponectin expression and secretion: in humans, an 
adiponectin promoter PPRE was identified [175] and PPAR  
agonists were able to induce transactivation of adiponectin 
promoter [176]. 
Apoptosis has proven to be important in the pathogenesis 
of liver fibrosis: in fact, fibrogenesis is accompanied by he-
patocyte apoptosis [177] and HSCs apoptosis is correlated 
with fibrosis regression [178]. It was demonstrated that 
TNF , a pro-inflammatory cytokine involved in apoptosis 
extrinsic pathway and in liver fibrogenesis, induces inhibi-
tion of PPAR  activity at post-translational level in HSCs 
[16]. Other authors studied the PPAR  interaction with death 
receptor (especially DR5) pathway and with apoptosis trig-
gered by C/EBP-alfa in HSCs, defining the role of PPAR  as 
a modulator of extrinsic pathway in HSCs apoptosis [144]. 
PPAR  also modulates intrinsic pathway of apoptosis in 
HSCs. Cidea (mithocondrial cell death-inducing DNA frag-
mentation factor  -like effector A), a proapoptotic factor 
implicated in mithocondrial apoptotic pathway, is a target 
gene of PPAR  [179]. 
Moreover, it has been demonstrated that the expres-
sion/activity of PPARs is positively modulated by the nu-
clear receptor FXR (Farnesoid X Receptor) [180]. These 
authors identified, in the PPAR  gene promoter, a sequence 
containing FXR-responsive element (FXRE). The bond be-
tween FXR and the promoter sequence leads to PPAR  gene 
transcription. The same authors also demonstrated the role of 
FXR-PPAR  crosstalk in inhibiting cytokine production and 
regulating inflammatory response of HSCs exposed to LPS. 
The cross-talk between these two nuclear receptors re-
presses, in turn, the synthesis of collagen- and  -SMA ex-
pression in activated HSCs [180]. 
Complex mechanisms, involving acetaldehyde pathway, 
the release of TNF-  and the activation of NF-kB signalling 
pathways, inhibit PPAR  expression during chronic alco-
holic liver disease [50].  
PPAR-  expression is downregulated in HSCs isolated 
from several animal models of liver fibrosis [19]. A number 
of studies have elucidated that PPAR  stimulation and ex-
pression inhibit HSCs activation and proliferation and, con-
sequently, collagen secretion, both in vitro and in vivo [4]. 
Indeed, when HSCs go from quiescent to activated phase, 
PPAR  expression gradually lower; this, strongly indicates 
the fundamental function of PPAR  in maintaining HSCs in 
a quiescent phase by controlling a panel of adipogenic tran-
scription factors, (CCAAT/enhancer binding protein LXR , 
and SREBP-1c), crosstalking and inhibiting a series of 
growth factors (TGF , PDGF, HGF), downregulating metal-
loproteins (MMP-2, MMP-9) and maintaining a dynamic 
balance between HSCs proliferative and apoptotic status [4, 
5, 144, 146, 181]. 
Interestingly, it was demonstrated that an adenovirus me-
diated PPAR  gene transfer prevents the development and 
ameliorates steatohepatitis and fibrosis in mice fed with me-
thionine choline deficient diet [181, 182]. 
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Further studies in vitro demonstrated that activated HSCs 
can be phenotypically and functionally reversed to quiescent 
HSCs by restored expression (via an adenoviral vector) or 
stimulated expression (via a selective agonist) of PPAR-  
[98, 183]. 
3.4. PPARs in Liver  Sinusoidal Endothelial Cells (LSEC) 
Capillarization of hepatic sinusoid (with losing of fenes-
tration) in cirrhosis has been a well-known condition since 
1963 [184] but only little knowledge exists on the control 
and reversal of this phenomenon. 
Previous studies demonstrated a protective role of 
PPAR  on endothelial function [185-187]. Interestingly, 
Rodrìguez-Villarupla and colleagues performed an elegant 
study in a murine model in cirrhosis evaluating the effects of 
PPAR  activation with fenofibrate [188]. They found a re-
duction of portal hypertension and an improvement of archi-
tectural abnormalities in rats treated with fenofibrate com-
pared to controls. Fenofibrate treated rats showed a marked 
reduction in portal hypertension and fibrosis and an increase 
in nodule size (this findings correlate with better prognosis in 
cirrhotic patients, [189]). A reduction in collagen I mRNA, 
 SMA and COX-1 protein expression and an increased 
availability of NO was also demonstrated [189]. 
Moreover, Xie G and colleagues found an interesting role 
of VEGF and NO in liver endothelial homeostasis [190]. The 
study demonstrated that maintenance of liver sinusoidal en-
dothelial cells (LSEC) differentiation in vitro requires VEGF 
stimulated NO working through soluble guanylate cyclase 
(sGC) activation plus VEGF working through an NO-
independent pathway. 
In vivo sGC can reverse LSEC capillarization in cirrhosis 
with a subsequent accelerated reversal of HSC activation and 
fibrosis [190]. The sGC activator has limited effect in vitro 
on HSC activation; if sGC activator is administered in co-
culture of activated HSCs plus capillarizated LSEC, there is 
an almost complete reversal of HSC activation and LSEC 
capillarization. VEGF-stimulated cGMP pathway is neces-
sary but not sufficient to maintain LSEC differentiation 
[190]. VEGF activates multiple pathways such as mitogen-
activated protein kinase (MAPK), focal adhesion kinase 
(FAK), phosphatidylinositol 3-kinase (PI3K/Akt), Phosphol-
ipase C-  (PLC- ) [191]. Although VEGF is a key factor in 
maintaining LSEC homeostasis, it is increased in cirrhosis, 
suggesting that capillarization is due to distruption of signal-
ling downstream VEGF. In fact, restoration of cGMP levels 
in vivo showed to be sufficient to normalize LSEC pheno-
type, allowing to hypothesize that a defect in NO/sGC/cGMP 
pathway is responsible for LSEC capillarization.  
Therefore, PPAR  may be an important and useful target 
for future therapeutic strategy on LSEC. 
4. PPARs STIMULATION STRATEGIES THERAPY 
In the liver of healthy subjects, the process of fibrogene-
sis is counterbalanced by that of fibrolysis. On the contrary, 
liver fibrosis begins when this mechanism is dysregulated 
causing a huge accumulation of extracellular matrix. 
Pivotal studies have demonstrated that liver fibrosis is 
not always an irreversible condition provided that underlying 
etiological agents are removed, as has been the case with 
secondary biliary fibrosis, Hepatitis C, Hepatitis B, steatohe-
patitis, and autoimmune hepatitis [192].  
The ability to induce regression of advanced liver fibrosis 
or cirrhosis open new hope for antifibrotic treatments [193, 
194]. 
Important studies indicate that, after liver injury, a num-
ber of bone marrow-derived monocyte/macrophages is re-
cruited at the sites of liver inflammation contributing to myo-
fibroblast population and playing an important role in in-
flammation, regeneration, remodeling of extracellular matrix 
and fibrogenesis [195, 196]; however, HSCs contributing to 
> 80% of the collagen producing cells, are still considered to 
be the most important source of myofibroblasts in liver fi-
brosis and also the natural target of anti-fibrotic therapy 
[197, 198]. Indeed, activated HSCs may transdifferentiate 
into myofibroblasts or revert to quiescent HSCs [192].  
Due to the key role in contributing to regulate phenotype 
of HSCs, deeper researches in the field of molecular biology 
have been focused on PPARs in liver fibrosis; since PPARs 
are important regulatory transcription receptors in the liver 
[1], they emerge as fundamental targets of anti-fibrogenic 
treatments. Indeed, they may modulate several metabolic and 
inflammatory pathways by responding to signals through 
ligand activation of transcription. It is quite evident that a 
significantly decreased PPAR  expression favours HSCs 
activation, whereas ectopic PPAR  expression or PPAR  
ligands inhibit HSCs activation and favour the phenotypic 
reversal of activated to quiescent HSCs, in culture [4, 192, 
146]. 
Although long-term studies are needed to confirm effi-
cacy and safety of PPARs agonists, several studies seem to 
open more than one perspective in the field of antifibrotic 
therapy of the liver disease using PPARs agonists.  
According to some experts, since myofibroblasts or acti-
vated HSCs are involved in synthesizing collagen in ex-
tracellular matrix, the aim of antifibrotic therapy is to induce 
apoptosis of activated myofibroblasts or reverse phenotype 
from myofibroblast or activated HSCs to quiescent HSCs 
[192].  
To date, two principal classes of clinical drugs that target 
PPAR  and PPAR  are known: they are fibrates and thia-
zolidinediones which, respectively, decrease circulating fatty 
acids and triglycerides and increase insulin sensitivity in type 
II diabetes [199]. 
Here, we analyze clinical perspectives and feasibility in 
using agonists of PPARs as antifibrotic liver treatment. 
4.1. PPAR  Agonists 
A key function of PPAR  is to control liver inflammation 
by regulating acute phase protein in hepatocytes and to re-
duce triglyceride storage and adipose-tissue-derived circulat-
ing factors thus increasing insulin sensitivity [200] and ame-
liorating the level of liver fibrosis. 
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PPAR  has its major impact on regulation of genes en-
coding enzymes involved in mitochondrial and peroxisomal 
fatty acid  -oxidation in human hepatocytes [201].  
Several oncogenes (c-Ha-ras, jun and c-myc) and genes 
linked to cell cycle (control immediate early gene, rZFP-37) 
are also known to be responsive to PPAR  induction [202]; 
indeed, PPAR  is a key actor in the process of peroxisome 
proliferation, hypertrophy, cell proliferation and hepatocar-
cinogenesis as demonstrated in primary hepatocytes culture 
and in animal models [201]. PPAR  stimulation may sup-
press both spontaneous and induced hepatocyte apoptosis 
[202] through TNF  mediator; activation of the MEK/ERK 
signalling pathway as well as the p38 MAP kinase pathway 
and the transcription factor NF B are all important mecha-
nisms that suppress hepatocyte apoptosis in response to 
PPAR  agonists [202-204]. However, no increased risk of 
liver cancer has been hypothesized in humans due to the low 
level of expression of PPAR  and to the rare appearance of 
mutant forms compared to those observed in animal models 
[202]. 
The principal exogenous PPAR  agonists are: 
- PPAR  agonist Wy-14,643 (3) which, by preventing in-
trahepatic lipid accumulation, inhibits the development of 
methionine and choline deficient diet-induced steatohepatitis 
and reduces the level of liver fibrosis [205, 206]. In particu-
lar, it was observed that Wy-14,643, upregulating a set of 
target genes that promote fatty acid breakdown in the liver, 
was able to counteract hepatic triglyceride and lipid peroxi-
dation accumulation and this rapidly (within 12 days) re-
versed steatohepatitis [206]. 
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Interestingly, the increased ability of the liver to break 
down existing lipoperoxides strongly counteracts hepatic 
inflammation and fibrosis [207]. The precise mechanisms 
through which Wy-14,643 decreases liver fibrosis is a re-
duced activation of HSCs and Kupffer cells by means of a 
diminished release of cytokines by macrophages and other 
leukocytes [206]. 
The administration of WY14,643 in ethanol-fed mice 
also restored the induction of PPAR  target genes thus indi-
cating that this agonist prevents the effect of ethanol on 
PPAR  minimizing the post-translational modifications of 
the PPAR  DNA binding domain by acetaldehyde, improv-
ing fatty acid  -oxidation and preventing liver steatosis 
[208]. 
- To date, fibrate drugs fenofibrate (4), gemfibrozil (5), 
benzafibrate (6), ciprofibrate (7), and clofibrate (8) that are 
ligands of PPAR  receptor, have been used with success as 
adjunct therapies to decrease triglyceride and low density 
lipoprotein (LDL)-cholesterol levels and increase HDL-
cholesterol levels [209, 210]. 
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Fibrates activate PPAR  that stimulates the oxidation of 
free fatty acids in the liver, consequently diminishing the 
synthesis of triglycerides and triglyceride-rich lipoproteins 
[211, 212]. 
Activated PPAR  also inhibits the synthesis of apolipo-
protein (apo) C-III (that delays the catabolism of triglyc-
eride-rich lipoproteins) and favors the expression of the gene 
for lipoprotein lipase [213, 214]; this latter enzyme promotes 
hydrolyzation of triglycerides and phospholipids in triglyc-
eride-rich lipoproteins in plasma. Fibrates increase the level 
of HDL by [215]. 
•  enhancing the expression of the genes for both apo A-I 
and apo A-II, the 2 main apolipoproteins of HDL [216, 
217]  
•  increasing cell cholesterol efflux secondary to an induc-
tion of cell ABCA1 expression [218] 
•  decreasing SR-B1 in the liver [219]. 
Fibrates also lower LDL-C levels, decrease the concen-
tration of triglyceride-rich lipoprotein remnants and increase 
the LDL particle size [220-222]. 
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The PPAR  agonist clofibrate reduces the amount of fat 
in the liver and decreases the necroinflammatory injury in 
ethanol-fed rats [223]. 
The PPAR  agonist fenofibrate exerts multiple cellular 
functions and has a key role in the protection from oxidative 
stress induced injury. 
Furthermore, fenofibrate was demonstrated to have pro-
tective preischemic properties significantly attenuating the 
ischemic/reperfusion liver injury through the reduction of the 
oxidative stress markers and of the level of inflammatory 
mediator TNF-  [224]. This result was obtained thanks to its 
ability to lower the release of lipid peroxidation products and 
to enhance the expression of antioxidant enzymes such as 
superoxide dismutase and catalase in the rat liver. 
Of note, the dietary supplementation with the n-3 polyun-
saturated fatty acids, with eicosapentaenoic acid (9) and with 
docosahexaenoic acid (10) to a rat model of hepatic ische-
mia-reperfusion-injury favoured the activation of PPAR  
and the inhibition of NF-kB signalling pathway and of tran-
scription of pro-inflammatory cytokines, thus suppressing 
the hepatic ischemia-reperfusion-injury [225]. 
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An interesting research, based on the structure-activity 
relationship, showed that steric bulkiness and position of the 
distal hydrophobic tail part are critical for agonistic activity 
and selectivity of PPAR  [226]; in this study, performed on 
rat fed with non alcoholic fatty liver disease induced by cho-
line deficient high-fat diet, PPAR -selective activation pre-
vented or ameliorated liver dysfunction and delayed the pro-
gression of fatty liver to fibrosis [226].  
New advancements in this field might help to select the 
best compounds able to interact with PPAR  with the aim of 
more benefit and safety. 
4.2. PPAR  /  Agonists 
Several PPAR /  agonists are known: GW501516 (11), 
L165041 (12), GW0742 (13), KD3010 (14), GW1514 (15), 
Compound F (16), and GW610742 (17) [70]. 
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- Treatment with the high-affinity PPAR /  agonist 
(GW501516) enhances HDL levels [137].  
A two-week treatment with GW501516 also induces a 
reduction in liver fat content and in plasma triglycerides (due 
to the reduced triglyceride production from the liver) [227]. 
Interestingly, after a two-week treatment with GW50 
1516, diabetic db/db mice affected by insulin resistance and 
glucose intolerance, have an improvement of hepatic and 
peripheral insulin sensitivity, without weight loss [228]. An 
increased glycolysis, a highly activated pentose phosphate 
pathway as well as an enhanced fatty acid synthesis in the 
liver, are all regulatory molecular mechanisms through 
which PPAR /  activation reduces hepatic glucose output 
[228]. 
GW501516 was further demonstrated to be effective in 
MSG mice affected by metabolic syndrome. This compound 
improved insulin sensitivity, serum insulin and leptin levels, 
glucose and lipid metabolism [227]. These authors con-
cluded that pharmacological activation of PPAR  /  may be 
a useful preventive and therapeutic strategy in metabolic 
syndrome [229].  
Therefore, PPAR /  activation shows a pivotal role in 
maintaining the glucose-lipid homeostasis by stimulating 
fatty acid oxidation, inhibiting glucose and VLDL secretion 
from the liver, increasing circulating HDL levels; further-
more, PPAR /  regulates the inflammatory activity of 
macrophages via NF-kB suppressing iNOS and COX2 [230]. 
- Another PPAR /  agonist, L-165041, raises plasma 
cholesterol concentrations and HDL levels in insulin-
resistant db/db mice but has no effect on either glucose or 
triglycerides [231].  
In ethanol-fed rats, the elevated ethanol consumption 
causes the impairment of liver regeneration by inhibiting 
insulin signaling that mediates hepatocellular DNA synthe-
sis; the administration of L-165041 restored this function 
attenuating ethanol-induced hepatic injury and improving 
liver regeneration thus demonstrating to have protective liver 
effects [232]. This PPAR /  agonist also ameliorated hepatic 
insulin sensitivity by means of the increased insulin receptor 
binding, the increased signaling downstream through 
PI3K/Akt, which promotes cell survival, and the reduced 
DNA damage and lipid peroxidation [232]. 
Another study based on administrating L-165041, in vi-
tro, on culture of HSCs and, in vivo, on rat model of acute 
liver injury (not in chronic liver injury), put in evidence the 
presence of enhanced acute liver toxicity (high levels of 
PPAR /  expression in activated HSCs and low level of 
PPAR  expression and adipogenesis) [70]. In contrast with 
this result, the same authors ascertained, after L-165041 ad-
ministration, an increased expression of CRBP-I and LRAT 
(both involved in retinol esterification) during HSCs activa-
tion, thus demonstrating an important role of this compound 
in maintaining adequate vitamin A storage [69]. Since trans-
formation of HSCs in myofibroblasts is commonly associ-
ated with loss of vitamin A, the agonist L-165041 might be 
potentially useful to inhibit HSCs transformation.  
- Furthermore, the administration of PPAR  /  agonist 
GW0742 in wild-type and in PPAR /  -null mice treated 
with CCl(4) demonstrated to be useful in reducing hepatic 
toxicity by downregulating expression of proinflammatory 
genes [233].  
- An interesting dual study on CCl(4) treated mice and 
mice that underwent cholestatic liver injury by bile duct liga-
tion, showed hepatoprotective and antifibrotic effects of 
PPAR /  agonist KD3010 in comparison with control 
groups [233]. KD3010 did not decrease HSCs activation nor 
attenuated the change of their morphology but protected cul-
tured hepatocytes from starvation and CCl(4)-induced cell 
death, due to the reduced reactive oxygen species production 
[234]. 
As demonstrated by an interesting study [235], further 
progress on the choice of better PPAR  /  agonists might 
derive from molecular-structure-activity relationship re-
searches that may test more easily the potency and selectivity 
of these compounds.  
4.3. PPAR  Agonists 
Several therapeutic strategies, based on the use of PPAR-
  agonists able to stimulate inhibition of HSCs activation and 
proliferation and to favour induction of HSCs apoptosis have 
proven to be potential anti-fibrotic approaches. PPAR-  
stimulation now represents an important target for anti-
fibrotic therapy [4, 5, 16, 19]. Several PPAR  agonists are 
known (Fig. 3): 
- Thiazolidinediones: troglitazone (18), ciglitazone (19), 
pioglitazone (20), rosiglitazone (21), netoglitazone (22) and 
rivoglitazone (23). They are antidiabetic drugs that reduce 
insulin resistance and structurally derive from clofibric acid 
(24); they selectively bind to two histidine residues, H323 
and H449, of the PPAR  transcription factor [28]. Generally, 
the action of thiazolidinediones go against the TGF-  ex-
pression (consequently inhibiting the synthesis of procolla-
gen and the activity of transcription factors AP-1, STAT and 
NF-kB [97, 236]. 
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Also there is the mentioned TZD-induced effect of PPAR 
  in differentiation of adipose tissue, that stimulates differen-
tiation of small adipocytes (more insulin sensitive) and fa-
vors apoptosis of large adipocytes. TZD promotes the PPAR 
  mediated regulation of GLUT4 [237] and c-Cbl associating 
protein (CAP) [238].  
Due to their efficacy on low insulin resistance, thia-
zolidinediones were demonstrated to be of benefit in treating 
liver fibrosis consequent to metabolic syndrome [239]. 
The PPAR  agonist troglitazone showed to inhibit, in 
dose-dependent mode, HSCs proliferation and chemotaxis 
induced by PDGF and to regulate expression of proinflam-
matory genes [38]. 
Another study demonstrated that, only in an adiponectin-
mediated manner, troglitazone suppressed upregulation of 
collagen  1(I) and  SMA mRNA in HSCs isolated from 
wild-type mice [86]. 
Ciglitazone regulated, in vitro, the expression of the 
leptin receptor Ob-R in activated HSCs, whose function is 
actually to mediate HSCs proliferation; by stimulating 
PPAR  transcription factor, ciglitazone gave inhibitory effect 
on leptin-induced HSCs proliferation with a reversion of 
ERKs activation [240]. 
Both ciglitazone and troglitazone were abandoned after 
clinical trials that documented severe liver toxicity and side 
effects (oxidative stress, mitochondrial damage, accumula-
tion of toxic metabolites, overexpression of genes expressing 
adipocyte fatty acid binding protein and fatty acid translo-
case, exacerbation of fatty liver) as well as insurgence of 
severe liver failure and death [241].  
Pioglitazone demonstrated to inhibit hepatic fibrosis 
caused by CCl(4) and to have a protective role against hepa-
totoxicity, through inhibition of HSCs proliferation and in-
flammation [242]. 
Mice fed with methionine-choline deficient diet treated 
with adenovirus carrying PPAR  plus Rosiglitazone had a 
significant reduction of hepatic fibrosing steatohepatitis 
[243, 181, 182]. It was observed:  
 
 
Fig. (3). Schematic view of PPAR agonists and their actions on PPAR , PPAR /  or PPAR , or on both dual or pan PPARs. 
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•  a reduction of expression of TNF , IL-6 
•  a decrease of serum ALT level and oxidative stress 
•  a down-regulation of the expression of profibrogenic 
genes of TGF- , MMP-2 and MMP-9  
•  an up-regulation of the expression of adiponectin. 
Furthermore, in a murine model of liver fibrosis induced 
by Schistosoma japonicum infection, rosiglitazone alone or 
plus praziquantel, reduced inflammation and liver fibrosis by 
decreasing the hepatic expression of TGF- 1,  -SMA, types 
I & III collagens [244]. 
Interestingly, both Pioglitazone and Rosiglitazone caused 
much less frequent and severe hepatotoxicity than ciglita-
zone and troglitazone [245].  
However, a study on gene expression induced by rosigli-
tazone on hepatocytes in vitro, showed that many genes in-
volved in pharmacological PPAR targeted functions, were 
up-regulated including intracellular uptake and binding of 
fatty acids, hepatic ketogenesis, mitochondrial  -oxidation, 
peroxisomal  -oxidation, lipogenesis, lipolysis, lipoprotein 
metabolism, glucose/glycerol metabolism and bile acid bio-
synthesis and transport [245]. Rosiglitazone was also found 
to induce an increase of both liver weight and hepatic 
triglycerides in mice [241]. 
- Non-Thiazolidinediones insulin sensitizer PPAR  ago-
nist GW570 (not available, GlaxoSmithKline™) in a dose-
dependent manner inhibited HSCs activation and had anti-
fibrotic effects on cultured HSCs and on CCl(4) treated mice 
and mice that underwent cholestatic liver injury by bile duct 
ligation [246]. 
- The PPAR  agonist GW7845 (25) blocked the TGF 1-
mediated activation of Smad3 and the induction of collagen 
and PAI-1 expression without affecting HSCs proliferation 
or viability in a study in vitro on adipocytic human HSCs 
[183]. According to these authors, GW7845 may prevent 
adipocytic HSCs by acquiring a myofibroblastic phenotype 
during chronic liver injury [183]. 
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These results were confirmed in another in vitro study on 
HSCs rat in which GW7845 inhibited the growth of HSCs 
and TGF 1-induced CTGF expression, thus confirming itself 
as a potential antifibrotic compound in treating and prevent-
ing liver fibrosis [247]. 
- Another in vitro study showed that the PPAR  agonist, 
KR62776 (26), caused apoptosis of activated HSCs cells, 
decreased the  -smooth muscle actin levels and offered some 
protection against CCl(4)-induced hepatocellular damage 
[248]. 
- the endogenous ligand 15-Deoxy- 12,14-prostaglandin J2 
(15-d-PGJ2) (27) inhibited cell growth of rat HSCs, both 
through cell cycle arrest (G0/G1 phase arrest and prevention 
of cells from entering the S phase) and an increase in apopto-
sis; 15-d-PGJ2 also displayed antifbrotic effects through a 
marked inhibition of TGF 1-induced CTGF expression 
[249]. 
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Of note, the authors demonstrated that the methylxan-
thine derivate caffeine (28) upregulating the expression of 
PPAR  in hepatocytes, sensitizes these cells to the well-
known inhibitory effect of 15-d-PGJ2 on CTGF expression 
[249]. The inhibition of TGF -induced CTGF expression 
through a PPAR  dependent mechanism was confirmed in a 
study on human hepatoma cells [250]. 
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Quite recently, an interesting study, performed on a 
mouse model of liver injury induced by cholestasis or 
CCl(4), demonstrated the ability of 15-d-PGJ2 to signifi-
cantly reduce the recruitment of bone marrow-derived mono-
cyte/macrophage at the sites of inflammation, in a PPAR  
independent manner [251]. No decrease of migration of 
neutrophils, dendritic or T cells was observed. A significant 
inhibition of phagocytosis, and cytokine expression and an 
attenuation of liver inflammation and fibrosis were also 
documented [251]. 
- the natural polyphenolic compound curcumin (29) (the 
main yellow pigment of a popular spice, turmeric, widely 
used as a food colorant), is well tolerated and has slow toxic-
ity. 
No adverse effects have been found in subjects consum-
ing up to 150mg of curcumin daily [252]. Studies on its 
bioavailability demonstrated a poor absorption and rapid 
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metabolism resulting in low serum levels, limited tissue dis-
tribution and short half-life [252]. 
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The liver and intestinal mucosa seem to be the principal 
organs responsible for its metabolism [252].  
In humans, curcumin gives an anti-inflammatory re-
sponse by inhibiting the induction of COX-2 and iNOS; an 
anticarcinogenesis effect has been also suggested as the re-
sult of apoptosis [252]. 
Curcumin improved both acute and subacute rat liver in-
jury induced by CCl(4) [253]. According to some authors, it 
was able to prevent acute and subacute liver toxicity of 
CCl(4) through its antioxidant properties and its ability to 
inactivate NF-kB and pro-inflammatory cytokine production 
[254, 255]. Furthermore, benefits for liver from curcumin 
administration were confirmed in a rat model of cirrhosis 
induced by CCl(4), where this compound caused an impor-
tant decrease in GSH, GSH/GSSG ratio and total glutathione 
produced [256]. 
The administration of curcumin on culture-activated 
HSCs inhibited their proliferation and induced apoptosis 
[124]. This compound significantly inhibited cell growth and 
suppressed the expression of collagen- 1(I), fibronectin and 
 -SMA genes in HSCs [256]. 
Through a PPAR  manner, curcumin was also found to 
significantly reduce the expression of two autonomously 
functioning heterodimers T RI and T RII [257] that com-
pose the dimeric polypeptide TGF  [258]. This leads to 
TGF  signaling disruption in HSCs and favours a potent 
antifibrotic effect. Moreover, PPAR  activation curcumin 
mediated inhibits TGF -induced CTGF expression. Accord-
ing to these authors, the results of the study indicate that 
PPAR  crosstalks with TGF  signaling and imply that phar-
macological intervention via PPAR  activation can indeed 
block the profibrogenic TGF /Smad pathway and thereby 
inhibit HSCs activation and ameliorate hepatic fibrosis [259, 
260]. A reduction of PDGF and TGF  was also observed in a 
rat model of hepatic injury induced by CCl(4), after the ad-
ministration of curcumin that also attenuated oxidative 
stress, suppressing inflammation and inhibiting activation of 
HSCs [261]. 
According to other authors, curcumin, in a dose depend-
ent manner, induces gene expression of endogenous PPAR  
in activated HSCs through the interruption of PDGF and 
EGF signaling pathways by inhibiting tyrosine phosphoryla-
tion of their receptor and reducing the levels of phosphory-
lated phosphatidylinositol-3 kinase (PI-3K/AKT), ERK and 
the JNK [262, 263]. 
The effects of curcumin were also explored on a murine 
model of bile duct inflammation and liver damage in cholan-
giopathy where this compound showed to have anti-fibrotic 
effects blocking proliferation and activation of portal myofi-
broblasts by inhibiting ERK1/2 in a PPAR  manner [264]. 
Interestingly, administration of curcumin to mice fed 
with a methionine- and choline-deficient diet was able to 
reduce intrahepatic expression of fibrogenic genes and liver 
fibrosis; after its administration in cultured HSCs, secretion 
of tissue inhibitor of metalloprotease and generation of ROS 
were also diminished [265].  
Another interesting study in a rat model of liver fibrosis 
induced by CCl(4) was planned to search whether curcumin 
could have antioxidant effects increasing enzymes such as 
APE1. It was found that, after curcumin administration, liver 
injury and oxidative stress, together with TNF , NF-kB and 
HSCs activation, decreased; concomitantly, a re-elevation of 
APE1 mRNA and protein levels was noted, thus demonstrat-
ing a role of this antioxidant pathway activated in PPAR  
manner by curcumin [266]. 
A recent interesting study showed that curcumin was not 
only able to regulate HSCs activation but also the cell cycle 
progression of damaged hepatocytes inducing them to un-
dergo apoptosis by up-regulating its P53 level expression 
[267]. 
Of great importance, a recent study showed that curcu-
min inhibited the receptors of advanced glycation end-
products thus decreasing activation of HSCs, by means of 
PPAR  activation [268, 269]. 
Since curcumin is safe for human consumption, it may 
have a beneficial role in alcoholic liver disease, in acute liver 
injury, in chronic liver diseases. 
Interesting molecular studies have clarified the existence 
of several binding modes of ligands to the target protein; this 
may result in new clues for improving the binding affinity 
and selectivity of PPAR  [270] thus ameliorating the ability 
to treat liver fibrosis. 
- a new class of PPAR  ligands from the marine envi-
ronment was discovered in a Marine Sponge, Plakinastrella 
mamillaris, from Fiji islands: they might be potential agents 
in the treatment of fibro-inflammatory disorders [271]. From 
the isolation and molecular characterization of a library of 13 
oxygenated polyketides, the authors focus their interest on 3 
of these molecules: gracilioether B (30), gracilioether C (31) 
and Plakilactone C (32) [271]. These molecules can activate 
PPAR  with a potency of 20-90 fold less than that of rosigli-
tazone, but with a very similar efficacy in terms of receptor 
transactivation (approximated 80%). These three molecules 
increase the expression of SCD-1 in liver cells (SCD1 cata-
lyzes the rate-limiting reaction of mono-insatured fatty acid 
and plays an important role in fatty liver) and up-regulate 
PEPCK (a rate-limiting enzyme involved in gluconeogene-
sis) [271]. Gracilioether C and plakilactone C, but not 
gracilioether B, are able to induce expression of CD36, a 
scavenger receptor involved in the hepatic reuptake of oxi-
dized lipoprotein. 
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In contrast with the action of gracilioether B and plak-
ilactone C, gracilioether C activates PPAR  in a non-
covalent fashion and suppresses production of IL-6 and 
MCP-1 similarly to the rosiglitazone, thus allowing the hy-
pothesis that it could become an interesting anti-
inflammatory drug [271]. Further studies on these molecules 
may promise interesting results. 
4.4. Dual or  Pan PPARs Agonists 
Dual or pan PPAR agonists, that are PPAR ligands, able 
to bind two or more PPAR isoforms, thus acting simultane-
ously on insulin resistance, dyslipidemia and obesity, have 
been proposed for several years [272].  
The summation of benefit findings of each one of these 
PPARs agonists might help to treat simultaneously both 
hyperglicemia and obesity and dyslipidemia and then to have 
beneficial effects on liver fibrosis.  
Chiglitazar (33), a PPAR /  agonist, by suppressing the 
expression of genes for the key gluconeogenic enzymes 
PEPCK and G-6-Pase and upregulating mRNA expression of 
genes involved in NEFA oxidation, demonstrated to reduce 
insulin resistance and to improve glucose tolerance and lipid 
profiles in monosodium L-glutamate obese rats [273]. Unfor-
tunately, this study does not report data on liver fibrosis. 
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According to some authors, dual PPAR /  agonists might 
be useful in patients with non-alcoholic fatty liver disease 
but more data are necessary on long-term safety, efficacy 
and impact on liver related histologic outcomes of these 
compounds [274]. Bezafibrate, an old and well known fibric 
acid, is the first clinically tested pan PPARs (PPAR   /   ) 
activator that has demonstrated to lower cholesterol, triglyc-
eride, glucose and improve insulin resistance and HDL cho-
lesterol, maintaining a good safety profile [272]. 
Of great importance, bezafibrate, recently tested in a 
model of obese mice induced by monosodium glutamate 
treatment, was demonstrated to have beneficial effects on 
macro-and microvesicles in hepatocytes and to reduce non-
alcoholic fatty liver disease activity score [275]. 
An important structural and functional study on receptor-
ligand interactions showed that the prostacyclin analog ilo-
prost (34), could strongly interact with PPAR  and 
PPAR / . Interestingly, two unique hydroxy groups from 
iloprost, formed hydrogen bonds with Thr-279 and Ser-280 
of PPAR  and with Thr-252 and Thr-253 of PPAR /  [276]. 
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This biochemical detailed study is critical for opening 
new opportunities in treating several diseases and also liver 
fibrosis. Iloprost is a well known and safe medical com-
pound, analog of a physiological mediator derived from 
prostanoids (metabolites of arachidonic acid through the 
action of cyclooxygenase) and endowed with anti-platelet 
and arterial vasodilator abilities [277]. Iloprost is able to 
maintain vascular endothelial homeostasis regulating portal 
flow volume, hepatic microcirculation and acting as a local 
hormone to control HSCs function by means of specific cel-
lular receptors [(IP, a transmembrane G-protein coupled re-
ceptor) and PPAR  and PPAR / ] [278, 5, 279]. 
It is now clear that the prostacyclin actions in ameliorat-
ing hepatic content of glutathione and hepatocyte mitochon-
drial function [280, 281] as well as in favouring adipocyte 
differentiation of HSCs, thus maintaining them in a quies-
cent phase, might depend on its ability to bind PPAR  and 
PPAR / . 
Interestingly, since hypoxemia aggravates steatohepatitis 
and liver fibrosis in rats fed with a choline-deficient high-fat 
diet [282] due to vulnerability of fatty hepatocytes to anoxic 
injury [283], the ability of iloprost to ameliorate hepatic per-
fusion might be useful to slow down the development of 
steatohepatitis and liver fibrosis [284-286]. 
Finally, after a global analysis of gene regulation by 
PPAR  and PPAR    agonists in human hepatocytes, 
emerged that a large number of target genes are regulated in 
common by PPAR    and PPAR  agonists [245]; therefore, a 
large inter-individual and unpredictable response of patients 
to these compounds may be expected [245]. 
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Moreover, other dual or pan PPARs exist but they have 
been discontinued because of severe side effects including 
renal failure, fibrosarcomas, urinary tract cancer and anemia 
[287]. 
5. CONCLUSIONS 
PPARs are transcription factors that belong to the nuclear 
receptor superfamily; of the three known isotypes, PPAR  is 
principally assigned the task of regulating fatty acid  -
oxidation, PPAR /  acts prevalently on triglicerides metabo-
lism, on LPL, regulates inflammatory response and may 
upregulate the activity of PPAR , PPAR  increases insulin 
sensitivity and regulates triglyceride storage in adipose tissue 
and maintains HSCs in a quiescent phase.  
To date, PPAR  and PPAR  are target to develop more 
and more effective therapeutic strategies against steatohepa-
titis and insulin resistance, respectively, whereas PPAR /  
promises to become an interesting therapeutic target against 
metabolism of triglycerides, in the near future.  
Given the fact that all three PPARs are closely involved 
in the pathogenesis of liver fibrosis, it is intriguing to think 
that they might become common part of a therapeutic strat-
egy against liver fibrosis.  
The possibility of using medical compounds that simul-
taneously act against two or pan PPARs, already exists. Fur-
ther studies are, however, needed to search potential useful-
ness of these therapeutic strategies, warding off the threat of 
insurgence of toxicity or side effects. Therefore, it is impor-
tant to plan clinical studies that mainly focus on safety of 
these medical compounds. 
Moreover, some help to reach a better affinity and selec-
tivity of medical compounds versus PPARs might come 
from the interesting studies performed with X-ray crystallo-
graphic analysis; these have shown that the high-resolution 
crystal structures of the PPARs complexed with these ago-
nists will provide the structural basis for specific and versa-
tile binding mode of these ligands [288, 289]; they also 
might favour further development of drugs treating meta-
bolic diseases and thus fibrosis. 
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ABBREVIATIONS 
ACOX1 = Acyl-CoA oxidase 1 
ADD-1/SREBP-1 = Adipocyte determination and dif-
ferentiation factor 1/sterol re-
sponse element binding protein 1 
AF = Activation Function Region 
AP-1 = Activator Protein-1 
aP2 = Adipocyte fatty acid binding pro-
tein 
APMK, MAPK = Mitogen-activated protein kinase 
ApoA = Apolipoprotein A 
ApoC = Apolipoprotein C 
BMI = Body mass index 
C / EBP = CCAAT / enhancer binding pro-
tein 
C/EBP- , - , and   = C/EBP transcription factors 
CARM1 = (Coactivator-associated arginine 
methyltransferase 1 
CCl(4) = Carbon tetrachloride 
Cidea = Mithocondrial cell death-inducing 
DNA fragmentation factor alpha-
like effector A 
COUP-TFII = COUF Transcription factor 2 
COX = Cyclooxygenase 
CRBP-I = Cellular retinol-binding protein, 
type 1 
CTGF = Connective tissue growth factor 
ECM = Extracellular matrix 
EGF = Epidermal growth factor 
ERK = Extracellular factor-regulated 
kinases 
ERK = Extracellular signal-regulated 
kinase 
GK = Glucokinase 
GLUT4 = Insulin-responsive glucose trans-
porter 
GSH = Glutathione 
GSSG = Glutathione disulfide 
HDL = High density lipoprotein 
HNF = Hepatocyte nuclear factor 
HSC = Hepatic Stellate Cells 
IL = Interleukin 
iNOS = Inducible nitric-oxide synthase 
JNK = c-Jun N-terminal kinase 
LPL = Lipoprotein lipase 
LRAT lecithin = Retinol acyltransferase 
LTB4 = Leukotriene B4 
LXR  = Liver X receptor   
MCP = Monocyte chemotactic protein 1 
MED = Mediator complex 
MFP1/L-PBE = Hydratase-dehydrogenase 
multifunctional/bifunctional 
enzymes MMP = Metalloprotein 
MUFA = Monounsaturated fatty acid 
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N-CoR = Nuclear corepressor 
NF-kB = Nuclear factor-light-chain enhan-
cer of activated B cells 
NR = Nuclear Receptor 
PAI-1 = Plasminogen activator inhibitor-1 
PBP/MED1 = PPAR-binding pro-
tein/TRAP220/DRIP205/ media-
tor subunit 1 
PDGF = Platelet-derived growth factor 
PEPCK = Phosphoenolpyruvate car-
boxykinase 
PGC-1  = Peroxisome proliferator-activated 
receptor-  coactivator 1  
PI-3K/AKT = Phosphorylated phosphatidyli-
nositol-3 kinase 
PPAR = Peroxisome proliferator-activated 
receptor 
PPRE = (Peroxisome proliferator response 
element) 
PRIC = PPAR -interacting cofactor 
PRIP/NCoA6 = Nuclear receptor coactivator 6 
interacting protein 
PTL = Pancreatic Trygliceride Lipase 
RIP140 = Receptor Interacting Protein 140 
ROS = Reactive Oxygen Species 
RXR = Retinoid X receptor 
SCD-1 = Steaoryl- CoA desaturase-1 
sdLDL = Small dense LDL 
Smad = Small mother against decapenta-
plegic 
SMRT = Silencing mediator for retinoid 
and thyroid hormone receptors 
SRC1/p160 = Steroid receptor coactivator 1, 
p160 family 
SREBP-1c = Sterol response element binding 
protein 1c 
T-betaR = TGFbeta receptor 
TG = Triglyceride 
TGF = Transforming growth factor 
TNF = Tumor necrosis factor 
TNF  = Tumor necrosis factor 
T RI = Transforming growth factor-  
type-I receptor 
VLDL = Very Low density lipoprotein 
  SMA =  -smooth muscle actin 
 HNF4-RE =  hepatic nuclear factor 4 regula-
tory element 
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